Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice?

被引:20
|
作者
Pieri, Andrew [1 ]
Harvey, James [2 ]
Bundred, Nigel [2 ]
机构
[1] Wansbeck Gen Hosp, Northumbria NE63 9JJ, England
[2] Wythenshawe Hosp, Univ Hosp South Manchester, Nightingale Ctr, Manchester M23 9LT, Lancs, England
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 5卷 / 03期
关键词
Pleomorphic lobular carcinoma in situ; Breast cancer; Breast carcinoma; Carcinoma in situ; Guideline; Excision margin; Recurrence rate;
D O I
10.5306/wjco.v5.i3.546
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical significance of pleomorphic lobular carcinoma in situ (PLCIS) is a subject of controversy. As a consequence, there is a risk of providing inconsistent management to patients presenting with PLCIS. This review aims to establish whether the current guidelines for the management of PLCIS are consistent with current evidence. A systematic electronic search was performed to identify all English language articles regarding PLCIS management. The data was analysed, specifically looking at: incidence of concurrent disease, recurrence rates, long-term prognosis and PLCIS management. A search was also performed for PLCIS management guidelines for the United Kingdom, United States, Canada, Australia, Germany and pan-European. The results of the evidence analyses were compared to the guidelines in order to establish whether the recommended management is consistent with the published evidence. Nine studies (level 3-4 evidence), involving a total of 176 patients and five management guidelines (from United Kingdom, United States, Australia and pan-European) were included in the review. From the evidence, 46 of 93 (49%) patients were found to have PLCIS with concurrent invasive disease on excision specimen analysis. Regarding recurrence rates, 11 of 117 (9.4%) patients developed a recurrence of PLCIS. There were no instances of invasive disease or ductal carcinoma in situ (DCIS) on recurrence histology. There were no studies assessing long-term outcomes in PLCIS cases. With regards to the management guidelines, the Association of Breast Surgery (United Kingdom) and the National Breast and Ovarian Cancer Care (Australia) do not mention PLCIS. The National Comprehensive Cancer Network (United States) suggest considering excision of PLCIS with negative margins. The NHS Breast Screening Programme (United Kingdom) and the European Society of Medical Oncology (pan-European) recommend PLCIS should be treated as with DCIS. We conclude that high quality evidence to inform guidance is lacking, thus recommendations are relatively vague. However, based on the available evidence, it would seem prudent to treat PLCIS in a similar manner to DCIS. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:546 / 553
页数:8
相关论文
共 50 条
  • [1] Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast
    Desai, Amita A.
    Jimenez, Rafael E.
    Hoskin, Tanya L.
    Day, Courtney N.
    Boughey, Judy C.
    Hieken, Tina J.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (10) : 3064 - 3068
  • [2] Challenges in the management of pleomorphic lobular carcinoma in situ of the breast
    Masannat, Yazan A.
    Bains, Salena K.
    Pinder, Sarah E.
    Purushotham, Arnie D.
    BREAST, 2013, 22 (02): : 194 - 196
  • [3] Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast
    Amita A. Desai
    Rafael E. Jimenez
    Tanya L. Hoskin
    Courtney N. Day
    Judy C. Boughey
    Tina J. Hieken
    Annals of Surgical Oncology, 2018, 25 : 3064 - 3068
  • [4] Pleomorphic lobular carcinoma in situ
    King, Tari A.
    Reis-Filho, Jorge S.
    BREAST CANCER MANAGEMENT, 2013, 2 (05) : 375 - 384
  • [5] Genetic and Phenotypic Characteristics of Pleomorphic Lobular Carcinoma In Situ of the Breast
    Chen, Yunn-Yi
    Hwang, Eun-Sil Shelley
    Roy, Ritu
    De Vries, Sandy
    Anderson, Joseph
    Wa, Chrystal
    Fitzgibbons, Patrick L.
    Jacobs, Timothy W.
    MacGrogan, Gaetan
    Peterse, Hans
    Vincent-Salomon, Anne
    Tokuyasu, Taku
    Schnitt, Stuart J.
    Waldman, Frederic M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (11) : 1683 - 1694
  • [6] Outcomes of surgical treatment of pleomorphic lobular carcinoma in situ of the breast
    Desai, Amita
    Jimenez, Rafael
    Hoskin, Tanya
    Day, Courtney
    Hieken, Tina
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 563 - 563
  • [7] Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast
    Fasola, Carolina E.
    Chen, Jie Jane
    Jensen, Kristin C.
    Allison, Kimberly H.
    Horst, Kathleen C.
    BREAST JOURNAL, 2018, 24 (01): : 66 - 69
  • [8] Molecular Alterations in Pleomorphic Lobular Carcinoma In Situ (PLCIS) of the Breast
    Chivukula, M.
    Brufsky, A.
    Carter, G.
    Chandran, U.
    Lyons-Weiler, M.
    Dabbs, D. J.
    CANCER RESEARCH, 2009, 69 (24) : 765S - 766S
  • [9] PLEOMORPHIC LOBULAR CARCINOMA OF THE BREAST
    BENTZ, J
    CLAYTON, F
    LABORATORY INVESTIGATION, 1993, 68 (01) : A12 - A12
  • [10] Pleomorphic lobular carcinoma in situ: Current evidence and a systemic review
    Waziri, Umar
    Wazir, Ali
    Wells, Clive
    Mokbel, Kefah
    ONCOLOGY LETTERS, 2016, 12 (06) : 4863 - 4868